TD Cowen Starts Verona Pharma (VRNA) at Buy

TD Cowen analyst Tara Bancroft initiates coverage on Verona Pharma (NASDAQ: VRNA) with a Buy rating and a price target of $100.00.

The analyst comments "Ohtuvayre's early momentum is refreshing to see in this environment, and it should continue with a slight beat in Q1 (our $56MM vs cons of $53MM). Our $340MM 2025 estimate and peak estimate of $3.9B suggest robust use, but KOLs believe it could achieve ~10x and ~5x higher penetration in the same timeframes, respectively, and there are multiple upside levers. Init. at Buy with a $100 DCF-based PT."

For an analyst ratings summary and ratings history on Verona Pharma click here. For more ratings news on Verona Pharma click here.

Shares of Verona Pharma closed at $65.46 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating